MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/kead457

Медицинская библиотека · Rheumatology (Oxford, England) · 2024

Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy.

Keret Shiri, Henig Israel, Zuckerman Tsila, Kaly Lisa, Shouval Aniela, Awisat Abid, Rosner Itzhak, Rozenbaum Michael, Boulman Nina, Dortort Lazar Ariela, Molad Yair, Sabbah Firas, Naffaa Mohammad E, Hardak Emilia, Slobodin Gleb, Rimar Doron

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

Autologous hematopoietic stem cell transplantation (AHSCT) has been shown to improve long-term survival for early diffuse progressive SSc compared with CYC. CYC, however, does not provide a long-term benefit in SSc. The combination of MMF and rituximab is a potent alternative regimen. We aimed to retrospectively compare the outcomes of SSc patients who underwent AHSCT to patients who met the eligibility criteria for AHSCT but received upfront combination therapy with MMF and rituximab.

METHODS

Repeated assessments of modified Rodnan Skin Score (mRSS), forced vital capacity (FVC), and diffusing capacity (DLCO) values were conducted. Clinical improvement was defined as an mRSS decrease >25% or an FVC increase >10%. Event-free survival (EFS) was defined in the absence of persistent major organ failure or death.

RESULTS

Twenty-one SSc patients in the combination therapy group were compared with 16 in the AHSCT group. Age, sex and disease duration were similar between the two groups. Clinical improvement at 12 months was seen in 18 (86%) patients in the combination group compared with 13 (81%) in the AHSCT group (P = 0.7). The hazard ratio for EFS at 24 months favoured the combination group (HR = 0.09, P = 0.04). During follow-up, both groups exhibited a significant and comparable reduction in mRSS and an increase in FVC values at each time interval up to 24 months.

CONCLUSION

MMF and rituximab compared with AHSCT in SSc patients eligible for AHSCT resulted in similar skin and lung clinical improvement with a better safety profile at 24 months.

Для цитирования: Keret Shiri, Henig Israel, Zuckerman Tsila, Kaly Lisa, Shouval Aniela, Awisat Abid, Rosner Itzhak, Rozenbaum Michael, Boulman Nina, Dortort Lazar Ariela, Molad Yair, Sabbah Firas, Naffaa Mohammad E, Hardak Emilia, Slobodin Gleb, Rimar Doron. Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy.. Rheumatology (Oxford, England). 2024. DOI: 10.1093/rheumatology/kead457.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.